A multicenter study of CBD treatment for genetic epilepsy syndromes found meaningful seizure reduction in 64% of patients with rare 15q genetic disorders. The research provides real-world evidence supporting cannabidiol as a viable treatment option for these challenging, treatment-resistant epilepsies that typically respond poorly to conventional medications.
Cannabidiol in Epilepsy: Restoring Locomotion and Seizure Control.
A comprehensive review demonstrates CBD’s potential for seizure control while maintaining motor function in epilepsy models. This motor-sparing profile of CBD distinguishes it from traditional antiepileptics that often impair movement and coordination. The evidence supports CBD’s therapeutic value for treatment-resistant epilepsy patients.
Cannabinoid Clinical Trials: CBD Cortical Excitability Study
Clinical Takeaway In this randomized controlled trial, neither a low nor high single dose of CBD directly reduced cortical excitability or produced measurable sedation in healthy adults. These findings suggest that CBD's...
Alabama’s 1st Medical Cannabis Dispensary Plans to Open Next Month
✦ New CED Clinical Relevance #84High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Medical AccessState ProgramsPatient CareRegulationEpilepsy Why This MattersAlabama's first medical cannabis dispensary represents access...
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav …
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic CbdEpilepsyPharmaceutical CannabisClinical ResearchPediatric Medicine Why This MattersJazz Pharmaceuticals' continued research on Epidiolex represents the...
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav … – Investors
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic EpilepsyCbdPediatricsPharmaceuticalFda Why This MattersJazz Pharmaceuticals' continued research presentations on Epidiolex represent ongoing expansion of...
Medical marijuana is having a moment in clinical trials – USA Today
✦ New CED Clinical Relevance #86High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Clinical TrialsEvidence-Based MedicineResearchChronic PainEpilepsy Why This MattersThe increasing volume of rigorous clinical trials...
Marijuana Rescheduling Could ‘Unlock Research’ To Treat Rare Diseases, Father Of …
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Rare DiseasesPediatric MedicineResearch PolicyEpilepsyClinical Trials Why This MattersDEA rescheduling from Schedule I to Schedule...
Cresco Labs Awarded Texas Medical Cannabis License
✦ New CED Clinical Relevance #84High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic PolicyAccessThcPtsdEpilepsy Why This MattersTexas operates one of the most restrictive medical cannabis programs...
5 Essential Breakthroughs in Cannabis Neuromodulation
5 Essential Breakthroughs in Cannabis Neuromodulation Imagine a world where a simple plant could revolutionize the way we treat some of the most challenging health issues, from anxiety and depression to Alzheimer's...